Dr Peter Molloy

Firebrick Pharma has capped a successful year launching its product Nasodine Nasal Spray in the US, Singapore and will shortly launch in the Philippines in partnership with local pharmaceutical firm S.V More. The Philippines approach highlights a new business model for the Company where the aim is to partner Nasodine products and provide the partner with the right to manufacture locally, reducing costs for Firebrick. Executive Chairman, Dr Peter Molloy reveals what's in store for the Australian pharmaceutical innovator.

Firebrick Pharma has launched its Nasodine nasal spray product in the United States and Singapore. 

In this interview, Firebrick Pharma Executive Chairman Dr Peter Molloy explains more about the global opportunity for its proprietary nasal spray. 

Nasodine is a povidone-iodine based nasal spray that kills germs in the nose. 

Firebrick Pharma (ASX:FRE) Executive Chairman Dr Peter Molloy hosted a livestream event.

WHEN: 2nd February, 2023

TIME: 3PM AWST - 6PM AEDT

We encourage questions ahead of the livestream from investors and those interested in learning more about Firebrick Pharma.

Please send questions to info@firebrickpharma.com